Brian Skorney
Stock Analyst at Baird
(3.73)
# 793
Out of 4,711 analysts
106
Total ratings
45.33%
Success rate
9.67%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Initiates: Outperform | $46 | $23.99 | +91.75% | 1 | Dec 13, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $11.41 | +162.93% | 1 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Reiterates: Outperform | $72 | $45.18 | +59.36% | 2 | Dec 2, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.88 | +468.12% | 4 | Nov 29, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $26 → $20 | $6.28 | +218.47% | 6 | Nov 26, 2024 | |
| BIIB Biogen | Maintains: Outperform | $294 → $300 | $146.47 | +104.82% | 16 | Nov 15, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $44 → $50 | $41.51 | +20.45% | 4 | Nov 13, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $200 → $193 | $118.97 | +62.23% | 9 | Nov 7, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $80 → $95 | $92.57 | +2.63% | 2 | Nov 7, 2024 | |
| ALMS Alumis | Initiates: Outperform | $25 | $8.82 | +183.45% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $3.89 | +157.07% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $263.38 | -18.37% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $58 → $60 | $36.26 | +65.47% | 2 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $135.42 | +32.92% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $6.28 | +345.86% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $53.60 | +15.67% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $2 | $0.23 | +769.57% | 4 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $7.62 | +411.81% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $38.63 | +63.09% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $800 → $760 | $701.85 | +8.29% | 12 | Jun 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $397.27 | -18.19% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $25.86 | -61.33% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.50 | +10,700.00% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $5.75 | +4.35% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $3.08 | +9,640.26% | 3 | May 7, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $176.50 | - | 2 | Nov 14, 2017 |
Dyne Therapeutics
Dec 13, 2024
Initiates: Outperform
Price Target: $46
Current: $23.99
Upside: +91.75%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $11.41
Upside: +162.93%
Soleno Therapeutics
Dec 2, 2024
Reiterates: Outperform
Price Target: $72
Current: $45.18
Upside: +59.36%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.88
Upside: +468.12%
Enanta Pharmaceuticals
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $6.28
Upside: +218.47%
Biogen
Nov 15, 2024
Maintains: Outperform
Price Target: $294 → $300
Current: $146.47
Upside: +104.82%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Outperform
Price Target: $44 → $50
Current: $41.51
Upside: +20.45%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $200 → $193
Current: $118.97
Upside: +62.23%
Gilead Sciences
Nov 7, 2024
Maintains: Neutral
Price Target: $80 → $95
Current: $92.57
Upside: +2.63%
Alumis
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $8.82
Upside: +183.45%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $3.89
Upside: +157.07%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $263.38
Upside: -18.37%
Sep 23, 2024
Maintains: Outperform
Price Target: $58 → $60
Current: $36.26
Upside: +65.47%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $135.42
Upside: +32.92%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $6.28
Upside: +345.86%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $53.60
Upside: +15.67%
Apr 16, 2024
Downgrades: Neutral
Price Target: $20 → $2
Current: $0.23
Upside: +769.57%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $7.62
Upside: +411.81%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $38.63
Upside: +63.09%
Jun 28, 2023
Maintains: Neutral
Price Target: $800 → $760
Current: $701.85
Upside: +8.29%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $397.27
Upside: -18.19%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $25.86
Upside: -61.33%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.50
Upside: +10,700.00%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $5.75
Upside: +4.35%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $3.08
Upside: +9,640.26%
Nov 14, 2017
Downgrades: Neutral
Price Target: n/a
Current: $176.50
Upside: -